InChI key
LXMSZDCAJNLERA-ZHYRCANASA-N
InChI
1S/C24H32O4S/c1-14(25)29-19-13-15-12-16(26)4-8-22(15,2)17-5-9-23(3)18(21(17)19)6-10-24(23)11-7-20(27)28-24/h12,17-19,21H,4-11,13H2,1-3H3/t17-,18-,19+,21+,22-,23-,24+/m0/s1
SMILES string
CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]45CCC(=O)O5)[C@H]13
mp
207-208 °C (lit.)
正在寻找类似产品? 访问 产品对比指南
Biochem/physiol Actions
螺内酯是竞争性醛固酮受体拮抗剂。 用作保钾利尿剂。
signalword
Danger
hcodes
Hazard Classifications
Carc. 2 - Repr. 1B - STOT RE 2
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type P2 (EN 143) respirator cartridges
法规信息
新产品
此项目有
Adam D Karns et al.
Journal of clinical hypertension (Greenwich, Conn.), 15(3), 186-192 (2013-03-06)
Aldosterone inhibition with mineralcorticoid receptor antagonists (MRAs) is an effective treatment for resistant hypertension. Aldosterone synthase inhibitors (ASIs) are currently being investigated as a new therapeutic strategy to reduce aldosterone secretion from the adrenal gland. In this study, the efficacy
Aldosterone inhibition in patients with heart failure with preserved ejection fraction.
Lars H Lund et al.
JAMA, 310(2), 205-205 (2013-07-11)
Aldosterone inhibition in patients with heart failure with preserved ejection fraction.
Christopher J A Neil et al.
JAMA, 310(2), 204-204 (2013-07-11)
Patients' interest overlooked.
Prescrire international, 22(139), 148-148 (2013-07-20)
Alexander Gabor et al.
Hypertension (Dallas, Tex. : 1979), 61(5), 1083-1090 (2013-03-20)
A chronic increase in circulating angiotensin II (Ang II) activates an aldosterone-mineralocorticoid receptor-ouabain neuromodulatory pathway in the brain that increases neuronal activation in hypothalamic nuclei, such as the paraventricular nucleus (PVN) and causes progressive hypertension. Several models of chronic sympathetic
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持